dc.creator | Kostadima, E. | en |
dc.creator | Tsiodras, S. | en |
dc.creator | Alexopoulos, E. I. | en |
dc.creator | Kaditis, A. G. | en |
dc.creator | Mavrou, I. | en |
dc.creator | Georgatou, N. | en |
dc.creator | Papamichalopoulos, A. | en |
dc.date.accessioned | 2015-11-23T10:35:42Z | |
dc.date.available | 2015-11-23T10:35:42Z | |
dc.date.issued | 2004 | |
dc.identifier | 10.1183/09031936.04.00118404 | |
dc.identifier.issn | 0903-1936 | |
dc.identifier.uri | http://hdl.handle.net/11615/29668 | |
dc.description.abstract | A randomised double-blind placebo-controlled study was designed to evaluate the effects of a semisynthetic macrolide antibiotic, clarithromycin, on bronchial hyperresponsiveness to methacholine in patients with a diagnosis of asthma. Adult asthma patients undergoing treatment with budesonide 400 mug b.i.d. and salbutamol 200 mug p.r.n. less than twice weekly were studied. Arm A (16 males/six females, aged 48 +/- 16 yrs) received clarithromycin 250 mg b.i.d. for 8 weeks, arm B (eight males/12 females, aged 42 +/- 12 yrs) clarithromycin 250 mg t.i.d. and arm C (six males/15 females, aged 41 +/- 16 yrs) placebo dextrose tablets. Bronchial hyperresponsiveness was quantified by measurement of the provocative dose of methacholine causing a 20% fall in forced expiratory volume in one second (PD20). Median (interquartile range) PD20 in the three groups before and after treatment with clarithromycin were: arm A: 0.3 (0.1-1) and 1.3 (0.6-2) mg; arm B: 0.4 (0.1-0.9) and 2 (2-2) mg; and arm C: 0.4 (0.1-0.9) and 0.3 (0.1-0.6) mg, respectively. Serum free cortisol levels were determined and remained unchanged from baseline in the clarithromycin-treated patients. It is concluded that clarithromycin reduces the degree of bronchial hyperresponsiveness in patients with asthma. | en |
dc.source.uri | <Go to ISI>://WOS:000221466500013 | |
dc.subject | bronchial asthma | en |
dc.subject | bronchial hyperresponsiveness | en |
dc.subject | clarithromycin | en |
dc.subject | macrolides | en |
dc.subject | CHLAMYDIA-PNEUMONIAE INFECTION | en |
dc.subject | METHYLPREDNISOLONE ELIMINATION | en |
dc.subject | MYCOPLASMA-PNEUMONIAE | en |
dc.subject | IN-VITRO | en |
dc.subject | ROXITHROMYCIN | en |
dc.subject | TROLEANDOMYCIN | en |
dc.subject | ERYTHROMYCIN | en |
dc.subject | MACROLIDES | en |
dc.subject | CHILDREN | en |
dc.subject | AZITHROMYCIN | en |
dc.subject | Respiratory System | en |
dc.title | Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma | en |
dc.type | journalArticle | en |